Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acetazolamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 16/20 | 0.97 |
| ▸ | CA2 known ✓ | P00918 | 16/20 | 0.97 |
| ▸ | CA4 known ✓ | P22748 | 9/20 | 0.97 |
| ▸ | CA12 known ✓ | O43570 | 4/20 | 0.97 |
| ▸ | CA9 | Q16790 | 10/20 | 0.97 |
| ▸ | CA3 | P07451 | 4/20 | 0.97 |
| ▸ | CA6 | P23280 | 4/20 | 0.97 |
| ▸ | CA5A | P35218 | 4/20 | 0.97 |
| ▸ | CA7 | P43166 | 4/20 | 0.97 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.97 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.97 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | CA11 | O75493 | 1/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetazolamide SCHEMBL2557036 | 0.98 | CA1 (1.00) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL23219 | 0.98 | CA1 (1.00) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL2845106 | 0.97 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL15513954 | 0.97 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL11301585 | 0.97 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL30094028 | 0.97 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL40812 | 0.97 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL28346552 | 0.97 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL20553201 | 0.95 | CA1 (0.93) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL9390276 | 0.95 | CA1 (0.93) | CA1CA2CA9CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1932841-B1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORP (JP) | 2014-01-01 | — | — | EP | claimed |
| US-20100093789-A1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | claimed |
| EP-1932841-A1 | SULFONAMIDE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2008-06-18 | — | — | EP | claimed |
| US-20070179127-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-02 | — | — | US | claimed |
| EP-1932841-B1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORP (JP) | 2014-01-01 | — | — | EP | disclosed |
| US-8415372-B2 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20120189693-A1 | ORAL DOSAGE FORMS | ELITE LABORATORIES, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| WO-2010151745-A1 | ORAL DOSAGE FORMS | ELITE LABORATORIES, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| US-20100093789-A1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2130828-A1 | SULFONAMIDE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-7618984-B2 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| CN-101443771-A | Methods for the identification and functional characterization of agents that modulate ion channel activity | NOVASCREEN BIOSCIENCES (US) | 2009-05-27 | — | — | CN | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1932841-A1 | SULFONAMIDE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2008-06-18 | — | — | EP | disclosed |
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070179127-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093789-A1 | SULFONAMIDE COMPOUND | AKT1, ROCK1, ROCK2 | CA1 1139/4885CA2 102/4885CA4 546/4885 |
| US-20070179127-A1 | Sulfonamide compound | MYLK, MYLK2, MYLK3 | CA1 1134/4885CA2 40/4885CA4 528/4885 |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | CA1 904/4885CA2 104/4885CA4 967/4885 |
| US-20090048223-A1 | Sulfonamide compound | ALK, AKT1, ARAF | CA1 1496/4885CA2 163/4885CA4 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.